Boston Scientific Corporation (BSX)
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.
Boston Scientific (BSX) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Boston Scientific (BSX) closed at $102.41, indicating a -1.37% shift from the previous trading day.
Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report?
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boston Scientific Climbs 40.5% in a Year: What's Driving the Stock?
BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.
Boston Scientific (BSX) Surpasses Market Returns: Some Facts Worth Knowing
Boston Scientific (BSX) reached $106.53 at the closing of the latest trading day, reflecting a +1.86% change compared to its last close.
BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?
Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are Boston Scientific BSX and Medtronic MDT.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
BSX Raises 2025 Financial Outlook: What's Backing It?
Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.
BSX's Neuromodulation Arm Sees Growth: Q1 Highlights
Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.
I'm Buying Dividend Aristocrats At Bargain Basement Prices
Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-covered dividends. Both carry A/A+ rated balance sheets and have potential for strong total returns with a solid starting yield.
